Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: R1, R21, and R22 are independently an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. R2 is —NR4R5 or —N+≡C−. Alternatively, R1 and R2, taken together with the methine group to which they are bonded, are a moiety represented by the following structural formula: R3 is —NH2, —OH, —OC(O)H or —OR9. R5, R6 and R7 are independently —H or an amine protecting group. R8 is —H, —OH or —OR8. R9 is an alcohol protecting group. Also disclosed are methods of preparing these compounds.

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: 1

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: R1, R2, and R22 are independently an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. R2 is —NR4R5 or —N+≡C−. Alternatively, R1, and R2, taken together with the methine group to which they are bonded, are a moiety represented by the following structural formula: R3 is —NH2, —OH, —OC(O)H or —OR9. R5, R6 and R7 are independently —H or an amine protecting group. R8 is —H, —OH or —OR8. R9 is an alcohol protecting group. Also disclosed are methods of preparing these compounds.

Abstract: The present invention relates to a method of preparing a 1-nitro-3-substituted-3-amino-2-propanol diastereomer represented by Structural Formula I: 1

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: 1

Abstract: Disclosed are novel compounds, and methods of making the same, represented by Structural Formula II, IX or XXVII: The compounds can be used to prepare combinatorial libraries based on a multicomponent Ugi reaction.

Abstract: An enzyme is immobilized on a solid support and can react selectively with one enantiomer in an enantiomeric mixture. A methods of using the enzyme immobilized solid support in conjunct with a separating means to separate enantiomeric mixtures is described. An apparatus for separating an enantiomeric mixture using an enzyme immobilized on a solid support is also described.

Abstract: The present invention relates to a method of preparing a 1-nitro-3-substituted-3-amino-2-propanol diastereomer represented by Structural Formula I: In Structural Formula I, R is an amine protecting group, and R1 is an amino acid side-chain, a protected amino acid side-chain, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl group. The method involves contacting a 1-nitro-3-substituted-3-amino-2-propanone with a reducing agent to form a mixture of 1-nitro-3-substituted-3-amino-2-propanol diastereomers. The 1-nitro-3-substituted-3-amino-2-propanol diastereomers are then separated by simulated moving bed chromatography to obtain one or more 1-nitro-3-substituted-3-amino-2-propanol diastereomer.

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: 1

Abstract: The present invention relates to a method for the stereospecific synthesis of an enantiomer of a chiral amine, wherein the chiral amine has the formula R.sup.1 CH(NH.sub.2)R.sup.2. R.sup.1 and R.sup.2 are each independently selected from the group consisting of alkyl, aryl and heterocyclic and radicals. This method is particularly useful for stereospecifically synthesizing S-dolaphenine. The method involves contacting a chiral enantiomer of norephedrine with borane, within an aprotic solvent to form a complex for stereospecifically reducing oximes. The complex is then contacted with an oxime, thereby stereospecifically reducing said oxime to form an enantiomer of a chiral amine.

Abstract: The present invention relates to a method for the stereospecific synthesis of an enantiomer of a chiral amine, wherein the chiral amine has the formula R.sup.1 CH(NH.sub.2)R.sup.2. R.sup.1 and R.sup.2 are each independently selected from the group consisting of alkyl, aryl and heterocyclic and radicals. This method is particularly useful for stereospecifically synthesizing S-dolaphenine. The method involves contacting a chiral enantiomer of norephedrine with borane, within an aprotic solvent to form a complex for stereospecifically reducing oximes. The complex is then contacted with an oxime, thereby stereospecifically reducing said oxime to form an enantiomer of a chiral amine.

Abstract: An apparatus for decontaminating a liquid surfactant of a dioxane having a vapor pressure which is higher than the vapor pressure of the surfactant includes an elevated reservoir for dioxane-contaminated liquid surfactant and an elongate inclined conduit, which has an upper portion for receiving a stream of the contaminated liquid surfactant from the elevated reservoir and a lower portion for discharge of decontaminated liquid surfactant. A heat source is suitable for heating contaminated liquid surfactant in the elongate inclined conduit in an amount sufficient to cause the dioxane contaminant of the liquid surfactant to volatilize, thereby decontaminating the surfactant. A gas source is suitable for directing a gas through the inclined conduit to transport volatilized dioxane out of the conduit. A receptacle is connected to the elongate inclined conduit for receiving the decontaminated liquid surfactant discharged from the inclined conduit.

Abstract: The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized.This method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

Abstract: A method for decontaminating a liquid of a contaminant having a vapor pressure which is higher than the vapor pressure of the liquid. A contaminated liquid is directed through an inclined conduit. A gas is directed into the inclined conduit, whereby the gas contacts the liquid and transports the contaminant, which has volatilized in the inclined conduit, out of the inclined conduit, thereby decontaminating the liquid. The liquid is discharged from the inclined conduit.

Abstract: The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized.The method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

Abstract: This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds.

Abstract: A method and apparatus are disclosed for decontaminating a liquid surfactant of a dioxane having a vapor pressure which is higher than the surfactant. A contaminated liquid surfactant is directed through an inclined conduit. A gas is directed into the inclined conduit, whereby the gas contacts the surfactant and transports the dioxane contaminant, which has volatilized in the inclined conduit, out of the inclined conduit, thereby decontaminating the surfactant. The liquid surfactant is discharged from the inclined conduit.

Abstract: This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds and compositions for a number of pharmaceutical indications including (but not limited to): 1. central nervous system and psychiatric disorders (e.g., sleep disorders, epilepsy and other convulsive disorders, anxiety, psychiatric diseases, neurodegenerative diseases, fever); 2. chronobiological-based disorders (e.g., jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder); 3. endocrine indications (e.g., contraception and infertility, precocious puberty, premenstrual syndrome, hyperprolactinemia, growth hormone deficiency); 4. cancer and other proliferative diseases; 5. immune system disorders and conditions associated with senescence; 6. ophthalmological diseases; 7. animal breeding (e.g., regulation of fertility, puberty, pelage color).